MEDAREX/NEURO THERAPEUTICS TO DEVELOP ANTIBODY THERAPEUTICS.Medarex, Inc. (Nasdaq:MEDX), Princeton, N.J., and Neuro Therapeutics, Inc., Vancouver, Canada, a privately-held biomedical bi·o·med·i·cal adj. 1. Of or relating to biomedicine. 2. Of, relating to, or involving biological, medical, and physical sciences. company, have announced a collaboration through which the two companies expect to utilize Medarex's HuMAb-Mouse technology to develop fully human antibody therapeutics for central nervous system disorders Nervous system disorders A satisfactory classification of diseases of the nervous system should include not only the type of reaction (congenital malformation, infection, trauma, neoplasm, vascular diseases, and degenerative, metabolic, toxic, or deficiency . Under the terms of the collaboration, Neuro Therapeutics intends to contribute to the collaboration all of its targets which Neuro Therapeutics believes are amenable to antibody therapeutics over a several year term that may be extended by mutual agreement. The two companies plan to share equally in the preclinical and clinical development and subsequent commercialization of any resulting products. "We are pleased to be collaborating with Neuro Therapeutics," said Donald L. Drakeman, president and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Medarex. "Exploring the possibility of using fully human antibodies to help repair central nervous system injuries and disorders adds an exciting new dimension to antibody-based therapeutics, especially in this area where currently few therapies are available." "We believe that our collaboration with Medarex provides an enabling path forward in the development of advanced treatments for central nervous system injuries," said John Steeves, President of Neuro Therapeutics. "When the cutting edge technologies and clinical trial experience of Medarex are combined with the neural disorders knowledge and pre-clinical in vivo in vivo /in vi·vo/ (ve´vo) [L.] within the living body. in vi·vo adj. Within a living organism. in vivo adv. drug development efforts of Neuro Therapeutics, it creates exciting opportunities." Neuro Therapeutics, Inc., is a privately-held Canadian biotechnology company spun out from the University of British Columbia Locations Vancouver The Vancouver campus is located at Point Grey, a twenty-minute drive from downtown Vancouver. It is near several beaches and has views of the North Shore mountains. The 7. that focuses on the diagnosis and treatment of central nervous system disorders. For example, the company's lead technology involves a patent-pending process for the transient immunological suppression of myelin myelin /my·elin/ (mi´e-lin) the lipid-rich substance of the cell membrane of Schwann cells that coils to form the myelin sheath surrounding the axon of myelinated nerve fibers. surrounding a central nervous system injury site. Animal models of spinal cord injuries Spinal Cord Injury Definition Spinal cord injury is damage to the spinal cord that causes loss of sensation and motor control. Description Approximately 10,000 new spinal cord injuries (SCIs) occur each year in the United States. have shown that the temporary removal of myelin provides an environment that facilitates neuronal neu·ro·nal adj. Relating to a neuron. neuronal pertaining to or emanating from a neuron. neuronal abiotrophy see hereditary neuronal abiotrophy of Swedish Lapland dogs. repair. For more information about Neuro Therapeutics, visit its website at http://www.neurotherapeutics.com Medarex, Inc., is a biopharmaceutical company developing monoclonal antibody-based therapeutics to fight cancer and other life-threatening and debilitating de·bil·i·tat·ing adj. Causing a loss of strength or energy. Debilitating Weakening, or reducing the strength of. Mentioned in: Stress Reduction diseases. Medarex has assembled a broad platform of patented technologies for antibody discovery and development, including the UltiMAb(tm) Human Antibody Development SystemSM for the creation of high-affinity, fully human antibodies; T-12 DevelopmentSM offering the potential to move from target to trial in approximately 12 months; and Trans-Phage TechnologySM combining high throughput screening with fully human antibody development. Medarex creates and develops fully human antibodies for itself and others, offering a full range of antibody related capabilities, including pre-clinical and clinical development supported by cGMP manufacturing services. For more information about Medarex, visit its website at http://www.medarex.com. For more information, call (212) 699-2541. |
|
||||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion